Who can use Koselugo(Selumetinib)?

Selumetinib is an oral small-molecule kinase inhibitor and a selective inhibitor of mitogen-activated protein kinase kinase 1/2 (MEK1/2). 

Who can use Koselugo(Selumetinib)?

By inhibiting the activity of MEK1/2 proteins, it blocks the RAS/RAF/MEK/ERK signaling pathway, thereby suppressing tumor cell proliferation and survival.

Selumetinib is primarily indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in pediatric patients aged 2 years and older with neurofibromatosis type 1 (NF1). It can significantly reduce tumor volume and improve related clinical symptoms.

Selumetinib(Koselugo)
KOSELUGO (selumetinib) is indicated for the treatment of pediatric patients aged 2 years and older who have been diagnosed with neurofibromatosis type 1 (NF1) and present with...
RELATED ARTICLES
Dosage Overview: Selumetinib

Selumetinib is a targeted drug specifically designed for the treatment of neurofibromatosis type 1...

Tuesday, June 24th, 2025, 17:42
Selumetinib dosage

Selumetinib(Koselugo) has demonstrated significant clinical efficacy as a kinase inhibitor in pediatric patients...

Tuesday, June 24th, 2025, 16:51
/ 1
2 in total
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
Mailbox:Info@Lucius.La
Welcome To Consult
Ucius Pharmaceuticals (Lao) Co.,Ltd All Rights Reserved